Training Example: BALVERSA® (erdafitinib) – Review the Data, Give Your Score & Compare to the Real AI Evaluation

Industry Context — Common BS Fingerprints in Medical Devices, Pharma & Biotech
Generic Claims: advancing human health, breakthrough innovation, life-changing therapies, transforming patient outcomes…
Red Flags: FDA cleared used interchangeably with FDA approved, clinical claims without published study citations, breakthrough claims for incremental improvements, regulatory status implied but not specified…
Semantic Drift Patterns: homepage claims breakthrough but pipeline page shows preclinical only, FDA approved claims but only for one indication, marketed broadly, claims clinical evidence but links to poster presentations not published studies, claims global reach but regulatory approvals are single-market…
Proof Expectations: specific regulatory clearance numbers (FDA 510(k), CE, TGA), published clinical trial results with ClinicalTrials.gov registration, ISO 13485 and GMP certification details, peer-reviewed publication citations…

BALVERSA® (erdafitinib)

(https://balversa.com) 📸 Data Snapshot: May 29, 2026

Analyze the raw signals below. How would a machine score this business’s credibility?

Here are the exact signals captured from up to six pages of the site — the same raw inputs the evaluation engine analyzed. They are grouped by signal type so you can weigh each the way the machine does.

🏗️ Semantic Structure — heading hierarchy & page identity (Info Density · Commodity Fingerprint)
HOMEPAGE Homepage | BALVERSA® (erdafitinib) (https://balversa.com)
Title

Homepage | BALVERSA® (erdafitinib)

Meta

The official BALVERSA® patient site. See Full Safety and Prescribing Information.

H1 IT’S TIME TO SEE WHAT A TARGETED TREATMENT CAN DO FOR YOU
H2 BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery:
NAV_HEADER_REPEATED_BODY About Bladder Cancer | BALVERSA® (erdafitinib) (https://balversa.com/about-bladder-cancer/)
Title

About Bladder Cancer | BALVERSA® (erdafitinib)

Meta

Learn how altered Fiberblast Growth Factor Receptor (FGFR) genes play a role in advanced bladder cancer. See Full Safety and Prescribing Information.

H1 About Bladder Cancer
H2 What is bladder cancer (urothelial cancer)?
NAV_HEADER_REPEATED_BODY How BALVERSA® Works | BALVERSA® (erdafitinib) (https://balversa.com/about-balversa/how-balversa-works/)
Title

How BALVERSA® Works | BALVERSA® (erdafitinib)

Meta

Learn how BALVERSA® works differently from other treatments for advanced bladder cancer. See Full Safety and Prescribing Information.

H1 How BALVERSA® Works
H2 How does BALVERSA® work?
H2 Is BALVERSA® right for you?
NAV_HEADER_REPEATED_BODY Taking BALVERSA® | BALVERSA® (erdafitinib) (https://balversa.com/starting-balversa/)
Title

Taking BALVERSA® | BALVERSA® (erdafitinib)

Meta

Learn about starting on BALVERSA<sup>®</sup>. See Full Safety and Prescribing Information.

H1 Taking BALVERSA®
📝 The Narrative — clean text per page (Info Density · Semantic Coherence)
HOMEPAGE (https://balversa.com) Homepage | BALVERSA® (erdafitinib)
[IMG: Image of an older man with crossed arms and blue shirt looking into the distance. Blue and green circles border him]
[H1] IT’S TIME TO SEE WHAT A TARGETED TREATMENT CAN DO FOR YOU
[H2] BALVERSA® is a prescription medicine used to treat adults with bladder cancer (urothelial cancer) that has spread or cannot be removed by surgery:
which has a certain type of abnormal FGFR gene, andwho have tried at least one other medicine by mouth or injection (systemic therapy) that did not work or is no longer working.Your healthcare provider will test your cancer for certain types of abnormal FGFR genes and make sure that BALVERSA® is right for you.BALVERSA® is not recommended for the treatment of people who are eligible for and have not received prior PD-1 or PD-L1 inhibitor therapy.It is not known if BALVERSA® is safe and effective in children.
[IMG: Icon of a blue bladder with green liquid inside]
What is bladder cancer?Learn about bladder cancer and the FGFR geneWhat is FGFR?
[IMG: BALVERSAlogo, a green circle surrounded by four blue outward facing crescents]
About BALVERSA®See how BALVERSA® works, clinical trial results, and side effectsHow does BALVERSA® work?
[IMG: Icon with a green number 24 inside of a blue arrow rotating clockwise]
Taking BALVERSA®Find out what to expect with BALVERSA®Taking BALVERSA®
[IMG: Icon of two overlapping lined pages, one blue one green]
SupportSee what resources are available to youGet support
1446 chars
SUB-PAGE (https://balversa.com/about-bladder-cancer/) About Bladder Cancer | BALVERSA® (erdafitinib)
[H1] About Bladder Cancer
About Bladder CancerAbout Bladder Cancer
[IMG: Older man in a scarf, hat and sweater holding the hand of a woman in a forest. Blue and green circles border them]
[H1] About bladder cancer
[H2] What is bladder cancer (urothelial cancer)?
In bladder cancer (urothelial cancer), cells grow abnormally in the urinary bladder to form a tumor. Most bladder cancers start in the inner lining of the bladder, which is called the urothelium. If the tumor has spread nearby to bladder walls or lymph nodes, it's considered locally advanced. If it continued to spread outside of the bladder to other parts of the body, it's considered metastatic.Learn about the role of FGFR in bladder cancer.WHAT IS FGFR?Learn about the FGFR gene and what it means to have a tumor with an abnormal FGFR geneAbout FGFR
817 chars
SUB-PAGE (https://balversa.com/about-balversa/how-balversa-works/) How BALVERSA® Works | BALVERSA® (erdafitinib)
[H1] How BALVERSA® Works
About BALVERSA®How BALVERSA® Works
[H2] How does BALVERSA® work?
BALVERSA® is a drug that is called a kinase inhibitor. A kinase inhibitor is a substance that blocks a type of enzyme (a protein) called a kinase. Human cells have many different kinases, and they help control important functions.BALVERSA® works by stopping the activity of FGFR, which is present in the bladder cancer tumor cell as well as healthy cells throughout the body. Because BALVERSA® targets the FGFR protein and can affect all cells with this receptor, it may cause serious side effects.BALVERSA® is the first medicine of its kind approved by the FDA to treat people with advanced bladder cancer where the tumor carries a certain abnormal FGFR gene.FDA = U.S. Food and Drug Administration.
[H2] Is BALVERSA® right for you?
Talk to your doctor about whether BALVERSA® may be right for you. In order for you to receive BALVERSA®, your doctor must first test your cancer for certain types of abnormal FGFR genes. To do this, your doctor will send a tissue sample from your tumor to a lab for analysis. This can be done with tissue from a new biopsy or with tissue that was already removed, so you may not need an additional procedure.HOW WAS BALVERSA® STUDIED?See the results of the clinical study of BALVERSA®See study resultsBALVERSA® SIDE EFFECTSSee what kinds of side effects have been associated with BALVERSA®Learn about possible side effects
1445 chars
SUB-PAGE · THIN (https://balversa.com/starting-balversa/) Taking BALVERSA® | BALVERSA® (erdafitinib)
[H1] Taking BALVERSA®
Taking BALVERSA®Taking BALVERSA®
[IMG: Image of an older man with salt and pepper hair looking at another older man with glasses. Blue and green circles border them]
[H1] Taking BALVERSA®
Take BALVERSA® as prescribed by your doctor to give the medication the best chance to work.HOW TO TAKE BALVERSA®Learn about how to take BALVERSA® and what dose adjustments you might needTaking BALVERSA®
412 chars
🛡️ Trust Signals — reviews, proof links, trust-theatre flag (Trust & Proof)
0Review mentions (all pages)
0External proof links (all pages)
PageReviewsProof links
/ (home) 0 0
/about-bladder-cancer/ 0 0
/about-balversa/how-balversa-works/ 0 0
/starting-balversa/ 0 0
🔗 Identity & Technical Layer — schema JSON-LD: identity chains, entity gaps (Identity & Authority)
Homepage — no schema detected (entity gap)
/about-bladder-cancer/ — no schema detected (entity gap)
/about-balversa/how-balversa-works/ — no schema detected (entity gap)
/starting-balversa/ — no schema detected (entity gap)

Your Diagnosis

Before revealing the machine’s verdict, predict the BS score for each signal. Higher = more BS (more fluff, less verifiable substance). Drag each slider, then submit to compare your judgment against the engine.

Information Density 0 / 30
Read the Narrative & headings: do hard facts (prices, dates, numbers) outweigh fluff power-words?
Semantic Coherence 0 / 20
Compare the homepage promise against the sub-page reality. Do they hold the same line?
Trust & Proof 0 / 20
Weigh review mentions against actual external proof links. Claims without verification = theatre.
Commodity Fingerprint 0 / 15
Check headings & narrative against the industry clichés in the setup above.
Identity & Authority 0 / 15
Inspect the schema: is there real Organization/Person identity with sameAs links, or gaps?
Your predicted BS score 0 / 100
💡 Stuck? Reveal the heuristic lens — how the deterministic page-auditor reads each signal (no AI, pure pattern rules)

These are the structural rules a local, deterministic auditor applies — the same lens you can use to judge each signal. They describe what to look for, not this company’s result.

Information Density

Classify each sentence as substantive or hollow. Grounding markers — numbers, currencies, dates, technical units, named entities — outweigh marketing adjectives. When fluff sits right next to hard evidence, the fluff is forgiven.

Semantic Alignment

Pull the main entities out of the H1, then check whether they actually recur through the body. A page that announces one thing and then talks about another drifts. Headings with no real sentences underneath read as pseudo-substance.

Trust & Proof

Count trust words (review, testimonial, rating, verified) against real outbound proof links (Google, Trustpilot, Clutch, G2, Yelp). Lots of trust language with zero verification links is trust theatre. Unlinked logo galleries count against it.

Commodity Fingerprint

Look at how much sentence length varies. Natural writing varies its rhythm; templated or mass-produced copy is statistically uniform. Very low variation reads as commodity content — unless unique named entities break the pattern.

Identity & Authority

Inspect the JSON-LD. Is there an Organization or Person schema, and does it carry sameAs links to real external profiles (LinkedIn, socials)? Missing schema or no identity declaration signals an anonymous entity.

Want to apply this lens yourself? The free BS Indicator Chrome extension runs these heuristic checks live on any page. Bear in mind it is a single-page, deterministic tool — it relies only on pattern rules for the page in front of it and does not perform the cross-page semantic correlation this audit uses, so its readout is a starting lens, not the full verdict.

B
BS Level
Medical Devices, Pharma & Biotech
40.7 Avg BS

Based on 784 businesses audited.

BS Detector

Medical Devices, Pharma & Biotech BS: BALVERSA® (erdafitinib) (balversa.com)

https://balversa.com 📍 Industry: Medical Devices, Pharma & Biotech
32 BS / 100

This is a low-BS, highly regulated pharmaceutical site that prioritizes clinical definitions over marketing hyperbole. Its score is driven not by the presence of hot air, but by the technical omission of structured data and the failure to provide direct external proof paths for its valid clinical claims.

Info Density Power-words vs. Substance ratio.
10
33% BS
Semantic Coherence Homepage promise vs. Sub-page reality.
0
0% BS
Trust & Proof Verifiable evidence vs. Trust Theatre.
8
40% BS
Commodity Fingerprint Detection of industry clichés/templates.
4
27% BS
Identity & Authority Expert verifiability & Schema depth.
10
67% BS

Implement MedicalEntity and Drug schema in the JSON-LD to establish technical authority and link to the official FDA approval documents. Replace generic calls to action like See study results with specific, high-level clinical metrics such as Objective Response Rate (ORR) percentages. Provide outbound links to the specific ClinicalTrials.gov record (e.g., NCT02365597) to provide a verifiable proof path for clinical assertions. Fix the heading hierarchy on the taking-balversa sub-page to improve technical SEO and accessibility standards.

The website perfectly aligns with the Pharma & Biotech industry category. The content is strictly focused on a prescription medication, specific genetic biomarkers (FGFR gene), and regulatory status (FDA), which are the defining characteristics of this sector.

“The score of 32 is primarily driven by the Identity and Authority pillar (due to missing schema) and the Trust and Proof pillar (due to zero external proof links). The site is largely free of Semantic Drift and Information Density fluff, which are the most common sources of high BS scores in other industries.”

Verified Analysis Date: May 29, 2026 © 1EuroSEO Independent Evaluator — Non-Sponsored Result
Brand AI Reputation